Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 318:47-d · Pharmacies; Substituting Generic Drugs

Title
XXX: OCCUPATIONS AND PROFESSIONS
Chapter
318 · PHARMACISTS AND PHARMACIES
Status
current
Official source linked
Yes
Official source Copy section link

318:47-d Pharmacies; Substituting Generic Drugs. – Pharmacies, including mail-order pharmacies, may substitute generically equivalent drug products for all legend and non-legend prescriptions unless the prescribing practitioner handwrites "medically necessary" on each paper prescription, or uses electronic indications when transmitted electronically, or gives instructions when transmitted orally that the brand name drug product is medically necessary. In this section, "drug product" does not include a biological product. Source. 2002, 123:1. 2008, 23:1, eff. July 11, 2008. 2018, 164:3, eff. Jan. 1, 2019.

Copy link

Source note

Source. 2002, 123:1. 2008, 23:1, eff. July 11, 2008. 2018, 164:3, eff. Jan. 1, 2019.

Source history

  • 2002, 123:1
  • 2008, 23:1, eff. July 11, 2008
  • 2018, 164:3, eff. Jan. 1, 2019

Related materials

Bill relationships

  • 2026 HB1249 reference

    rvices and Elderly Affairs ----------------------------------------------------------------- ANALYSIS This bill amends the definition of the practice of pharmacy under RSA 318 and authorizes pharmacists to prescribe certain prescription devices necessary for the appropriate delivery or administration of a prescribed drug. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

  • 2026 HB1584 amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 HB1584-FN amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB504 reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB504-FN reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB665 amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB665-FN amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2025 HB117 amend

    he substitution of biological products. Be it Enacted by the Senate and House of Representatives in General Court convened: 163:1 Pharmacists and Pharmacies; Pharmacies; Substituting Biological Products. Amend RSA 318:47-dd to read as follows: 318:47-dd Pharmacies; Substituting Biological Products. I. In this section: (a) "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or d

  • 2025 HB254 reference

    ician licensed pursuant to RSA 329; (2) An osteopathic physician licensed pursuant to RSA 329; (3) An advanced practice registered nurse licensed pursuant to RSA 326-B; or (4) A pharmacist licensed pursuant to RSA 318; provided, however, that a pharmacist shall not qualify as an attending health care provider under RSA 137-M:1, II or as a consulting health care provider under RSA 137-M:1, III. (b) A "health care provider" d

  • 2025 HB63 reference

    may write a prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine for the postsecondary educational institution or independent school. IV. A pharmacist licensed under RSA 318 may dispense a valid prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine issued in the name of a postsecondary educational institution or an independent school. 200